International Flavors & Fragrances Inc.
NYSE•IFF
CEO: Dr. Jennifer Amy Johnson Ph.D.
セクター: Basic Materials
業種: Chemicals - Specialty
上場日: 1974-12-17
International Flavors & Fragrances Inc., together with its subsidiaries, manufactures and sells cosmetic active and natural health ingredients for use in various consumer products in the United States, Europe, and internationally. It operates through four segments: Nourish, Health & Biosciences, Scent, and Pharma Solutions. The Nourish segment offers natural and plant-based specialty food ingredients, such as flavor compounds used in savory products; beverages; sweets; and dairy products. It also provides value-added spices and seasoning ingredients; savory solutions, including spices, sauces, marinades, and mixtures; and natural antioxidants and anti-microbials. The Health & Biosciences segment develops and produces enzymes, food cultures, probiotics, and specialty ingredients for food and non-food applications. Its Scent segment provides fragrance compounds, which include fine fragrances comprising perfumes and colognes, as well as consumer fragrances; fragrance ingredients comprising synthetic and natural ingredients that include natural flavor extracts, specialty botanical extracts, distillates, essential oils, citrus products, aroma chemicals, natural gums, and resins; and cosmetic active ingredients consisting of active and functional ingredients, and delivery systems for cosmetic and personal care product industries. Its Pharma Solutions segment produces and sells cellulosics and seaweed-based pharma excipients. The company sells its products primarily to manufacturers of perfumes and cosmetics, hair and other personal care products, soaps and detergents, cleaning products, dairy, meat and other processed foods, beverages, snacks and savory foods, sweet and baked goods, dietary supplements, infant and elderly nutrition, functional food, and pharmaceutical excipients and oral care products. International Flavors & Fragrances Inc. was incorporated in 1909 and is headquartered in New York, New York.
連絡先情報
時価総額
$20.02B
PER (TTM)
-57.5
29.5
配当利回り
2.0%
52週高値
$84.45
52週安値
$59.14
52週レンジ
順位47Top 61.9%
3.4
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 3.4 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025
財務ダッシュボード
Q4 2025 データ
売上高
$2.59B+0.00%
直近4四半期の推移
EPS
$0.07+0.00%
直近4四半期の推移
フリーCF
$132.00M+0.00%
直近4四半期の推移
2025 Annual 決算ハイライト
主なハイライト
Comparable Sales Growth Achieved Net sales increased 2% on a comparable currency neutral basis in 2025 versus 2024, despite reported sales decline of 5% to $10.890B.
Gross Margin Expansion Gross margin reached 36.2% in 2025, improving 30 basis points compared to 35.9% reported in 2024.
Segment Performance Strength Taste and Food Ingredients segments showed strong comparable currency neutral Adjusted EBITDA growth of 10% each in 2025.
Major Divestiture Activity Completed divestitures of Pharma Solutions and Nitrocellulose groups in 2025, streamlining core business focus.
リスク要因
Significant Goodwill Impairment Recorded $1.153B goodwill impairment charge in 2025, primarily impacting the Food Ingredients reporting unit.
Operating Profit Deterioration Reported operating loss of $(382)M in 2025, contrasting sharply with $766M profit achieved in 2024.
Input Cost Inflation Pressure Increases in raw material, transportation, and energy costs exacerbated by inflation pressure profitability outlook.
Competitive Market Dynamics Intense global competition and customer reliance on "core lists" may adversely affect sales and margin realization.
見通し
Strategic Segment Realignment Completed restructuring Nourish segment into Taste and Food Ingredients effective January 1, 2025 for better focus.
Share Repurchase Authorization Board authorized new $500M share repurchase program commencing October 1, 2025, supporting capital allocation goals.
Productivity Program Timeline IFF Productivity Program initiatives are targeted for substantial completion by December 31, 2026 to enhance efficiency.
2026 Capital Spending Guidance Expect capital spending in 2026 to be approximately 6% of sales, reflecting prioritized project evaluation.
同業比較
売上高 (TTM)
$48.69B
$39.97B
$30.15B
粗利益率 (最新四半期)
47.2%
41.1%
40.8%
主要指標
銘柄コード | 時価総額 | PER (TTM) | ROE (TTM) | 負債比率 |
|---|---|---|---|---|
| PPG | $26.31B | 16.8 | 33.6% | 93.6% |
| DOW | $23.21B | -8.9 | -15.5% | 33.5% |
| PAAS | $22.68B | 26.5 | 16.9% | 9.6% |
長期トレンド
直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
-3.1%
横ばい
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
100%
優れたキャッシュフローの実績
深度リサーチ
次回決算:2026年5月4日
EPS:-
|売上高:-
財務データ
決算説明会
財務レポート
ニュース
損益計算書
バランスシート
キャッシュフロー計算書
財務比率
変化率
損益計算書 | 直近12ヶ月 |
|---|
データなし